RE: WHO to restart COVID drug trial with focus on immune responses11 May 2021 12:41
High Ahfam,
looking through and cross referencing ie Covid 10, Interleukins, granulyte macrophage colony stimulating factor, macrophages, CD4 positive cells T helper cells) CD4 (T killer cells) there is also a regulator cell too, and this is decided by Interferon gamma, Interferons, STAT pathways, Tyk 2 inhibitors Jak 1, 2 and 3 inhibitors and many other subjects mainly from Wikipedia which is pretty well up to date.
Tyk 2 also regulate IL-7 and IL-12 ( IL-12) will signal Interferon gamma. Tyk 2 signals via STAT 5 pathway whilst Jak1 signals via STAT 3 pathway'
All looks very very very promising. Tyk 2 has limited targets and hence can be made far more selective. JAK 3 reacts with too many Interleukins!. JAk 3 also requires Jak 1( Jak 3 requires Jak 1 to work in partnership or will not work at all)
Jak1 and Jak 3 only inhibitors will run the risk of very high risk of serious side effects ( That is why they have had NDA issued black box warnings)
JAK 2 is effective but here again reacts with too many Interferons etc, and hence has side effects due to interferon production of which we need, being halted and hence counter productive. More associated health risks with this one.
TYK2 more selective thanJAK 2 without associated side effects.
I have cross referenced with the description of our patented TYK2 and my current conclusion, so far is looking good to satisfy CTA requirements.
One thing I have concluded is
There does not exist a first generation of JAK 1, Jak 2 or JAK or any combination that will be suitable to treat immuno diseases sucessfullly due to the above lack of selectivity.
As far as I can see, and someone please correct me if I am wrong, that we have certainly no serious competition in any shape or form,with regards to not only Covid19 but also the original targets of intent.
Regards all